MLICM
HOWL icon

Metropolitan Life Insurance Company (MetLife)’s Werewolf Therapeutics HOWL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,460
Closed -$101K – 2440
2021
Q4 		$101K Buy
+8,460
New +$128K ﹤0.01% 2475

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s HOWL Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Werewolf Therapeutics (HOWL) in Q1 2022, closing a stake of 8,460 shares — an estimated $101K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in HOWL in Q4 2021 and held it in 1 quarter. The position peaked at $101K in Q4 2021. 49 funds tracked by Wall St. Rank hold HOWL as of Q1 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Werewolf Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 8,460 Werewolf Therapeutics shares in Q1 2022, an estimated $101K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Werewolf Therapeutics position peaked at $101K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.